Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00540-5/fulltext?dgcid=hubspot_update_feature_updatealerts_lanonc&utm_campaign=update-lanonc&utm_medium=email&_hsmi=290040916&_hsenc=p2ANqtz-_oxWQHU5ZpT-s3oobCiZ0tGph9nPCYoAgwz_irnVOFArNlyItm3PaTQwNf77qVHBx2aljJYxJjBM54GJeGvEmf1qmyFA&utm_content=289772750&utm_source=hs_email